Mechanisms and Treatment of Extraosseous Calcification in Chronic Kidney Disease

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2011 Jul 20

PMID 21769106

Citations 30

Authors

Markus Ketteler

Hansjorg Rothe

Thilo Kruger

Patrick H Biggar

Georg Schlieper

Affiliations

Soon will be listed here.

Abstract

Strong and unidirectional associations exist between the severity of cardiovascular calcifications and mortality in patients with advanced chronic kidney disease. In the past 10 years, a wealth of experimental and clinical information has been published on the key pathophysiological events that contribute to the development and progression of vascular and soft-tissue calcifications. These processes involve a sensitive balance of calcification inhibition, induction and removal. The traditional view of regarding secondary hyperparathyroidism and elevated calcium × phosphate product as the pivotal risk factors for calcification has been challenged by data demonstrating a role for other, more subtle and complex pathomechanisms. These mechanisms include the loss of endogenous calcification inhibitors, deficient clearance of calcified debris, effects of vitamin K and vitamin D, and the action of calcification inducers as in osteogenic transdifferentiation. In this Review, we describe our current knowledge of the factors involved in the passive and active regulation of extraosseous calcification processes, with an assessment of their importance as targets for future diagnostic and therapeutic interventions.

Citing Articles

Meta-analysis of the correlation between pulmonary hypertension and echocardiographic parameters in patients with chronic kidney disease.

Jin J, Hao W, Xie D PeerJ. 2024; 12:e17245.

PMID: 38650651 PMC: 11034503. DOI: 10.7717/peerj.17245.

Affinity targeting of therapeutic proteins to the bone surface-local delivery of sclerostin-neutralizing antibody enhances efficacy.

Zhang B, Swanson W, Durdan M, Livingston H, Dodd M, Vidanapathirana S J Bone Miner Res. 2024; 39(6):717-728.

PMID: 38526976 PMC: 11472147. DOI: 10.1093/jbmr/zjae050.

Gut microbial metabolites SCFAs and chronic kidney disease.

He M, Wei W, Zhang Y, Xiang Z, Peng D, Kasimumali A J Transl Med. 2024; 22(1):172.

PMID: 38369469 PMC: 10874542. DOI: 10.1186/s12967-024-04974-6.

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.

Brandenburg V, Ketteler M Nutrients. 2022; 14(15).

PMID: 35893866 PMC: 9330693. DOI: 10.3390/nu14153009.

Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule.

Young K, Beggs M, Grimbly C, Alexander R Exp Biol Med (Maywood). 2022; 247(13):1103-1111.

PMID: 35482362 PMC: 9335508. DOI: 10.1177/15353702221091982.

References

Shroff R, McNair R, Figg N, Skepper J, Schurgers L, Gupta A . Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008; 118(17):1748-57. DOI: 10.1161/CIRCULATIONAHA.108.783738. View

Jono S, McKee M, Murry C, Shioi A, Nishizawa Y, Mori K . Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87(7):E10-7. DOI: 10.1161/01.res.87.7.e10. View

de Francisco A, Leidig M, Covic A, Ketteler M, Benedyk-Lorens E, Mircescu G . Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010; 25(11):3707-17. PMC: 2957591. DOI: 10.1093/ndt/gfq292. View

Mathew S, Lund R, Chaudhary L, Geurs T, Hruska K . Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19(8):1509-19. PMC: 2488263. DOI: 10.1681/ASN.2007080902. View

Towler D . Inorganic pyrophosphate: a paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol. 2005; 25(4):651-4. DOI: 10.1161/01.ATV.0000158943.79580.9d. View

Koos R, Mahnken A, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger J . Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005; 96(6):747-9. DOI: 10.1016/j.amjcard.2005.05.014. View

Mathew S, Tustison K, Sugatani T, Chaudhary L, Rifas L, Hruska K . The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008; 19(6):1092-105. PMC: 2396927. DOI: 10.1681/ASN.2007070760. View

Wolf M . Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010; 21(9):1427-35. DOI: 10.1681/ASN.2009121293. View

Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y, Ikegawa S . Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet. 1998; 19(3):271-3. DOI: 10.1038/956. View

10.

Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X . The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats. Eur J Pharmacol. 2009; 616(1-3):306-13. PMC: 6854701. DOI: 10.1016/j.ejphar.2009.05.013. View

11.

Chan K, Lazarus J, Thadhani R, Hakim R . Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20(10):2223-33. PMC: 2754104. DOI: 10.1681/ASN.2009030319. View

12.

Schurgers L, Spronk H, Soute B, Schiffers P, Demey J, Vermeer C . Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood. 2006; 109(7):2823-31. DOI: 10.1182/blood-2006-07-035345. View

13.

Ix J, Shlipak M, Sarnak M, Beck G, Greene T, Wang X . Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int. 2007; 72(11):1394-9. DOI: 10.1038/sj.ki.5002549. View

14.

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

15.

Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K . Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis. 2004; 44(4):680-8. View

16.

Caglar K, Yilmaz M, Saglam M, Cakir E, Acikel C, Eyileten T . Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2007; 3(1):61-8. PMC: 2390988. DOI: 10.2215/CJN.02810707. View

17.

Schlieper G, Brandenburg V, Ketteler M, Floege J . Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009; 5(9):539-43. DOI: 10.1038/nrneph.2009.99. View

18.

ONeill W, Lomashvili K, Malluche H, Faugere M, Riser B . Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int. 2010; 79(5):512-7. PMC: 3183997. DOI: 10.1038/ki.2010.461. View

19.

van der Sluis I, Boot A, Vernooij M, Meradji M, Kroon A . Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up. Eur J Pediatr. 2006; 165(9):590-3. DOI: 10.1007/s00431-006-0146-8. View

20.

Ho A, Johnson M, Kingsley D . Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000; 289(5477):265-70. DOI: 10.1126/science.289.5477.265. View